Learn how semaglutide for prediabetes may help support blood sugar balance and weight management. Explore the latest research, safety tips, and clinical guidance.
Prediabetes affects more than 1 in 3 adults in the U.S. and raises the risk of developing type 2 diabetes, cardiovascular disease, and other chronic illnesses. While diet and exercise remain foundational, new evidence suggests that medications like semaglutide may offer additional support.
Though not FDA-approved specifically for prediabetes, semaglutide is being studied for its ability to reverse impaired glucose regulation and improve metabolic health in at-risk individuals.
Prediabetes is a state where blood glucose levels are elevated but not high enough to qualify as type 2 diabetes:
Without intervention, up to 70% of prediabetics may develop full diabetes within 5 years. Early strategies are key.
Semaglutide is a GLP-1 receptor agonist that mimics natural incretin hormones. Its metabolic actions include:
These effects support both blood sugar control and weight loss, making semaglutide a strong candidate for prediabetes care.
In a major pooled analysis from the STEP trials, up to 89% of participants with prediabetes reverted to normoglycemia after 68 weeks of semaglutide therapy.
In the STEP 8 head-to-head trial, semaglutide showed superior reversal of prediabetes vs. liraglutide (89.5% vs. 64.9%).
Semaglutide's metabolic effects are closely tied to body weight reduction. In the STEP 1 trial:
Your licensed healthcare provider will determine the optimal format and schedule.
Semaglutide works best alongside daily health strategies, such as:
Not approved for pregnancy or breastfeeding. Always disclose full medical history before starting.
Eden streamlines GLP-1 access by offering:
If deemed appropriate, Eden-affiliated providers prescribe FDA-approved semaglutide via trusted U.S. pharmacies.
Though not FDA-approved for prediabetes, semaglutide has shown strong evidence of reversing early glucose abnormalities and reducing the risk of type 2 diabetes when paired with lifestyle changes. Results from the STEP trials show that the FDA-approved versions of semaglutide helped the majority of patients normalize blood sugar and significantly reduce body weight.
If you've struggled to manage prediabetes through lifestyle alone, consult a licensed medical provider. Eden can help you explore safe, science-backed options.
This article is for educational purposes only and does not replace medical advice. Semaglutide should only be used under the care of a licensed healthcare provider. Eden connects individuals with clinicians who may prescribe GLP-1 medications post-assessment if you are considered an eligible candidate. Eligibility is not guaranteed.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
No, but it may be prescribed if deemed appropriate by an independent, licensed healthcare provider, if so determined.
Yes. Over 80% of participants in STEP trials achieved normal glycemia after 68 weeks.
It depends. Some patients use it short-term; others benefit from longer use.
Absolutely. Diet, activity, and stress control amplify semaglutide's benefits.
A licensed medical provider will assess your health and help determine if semaglutide is appropriate.
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obesity and Metabolism, 25(1), 18–35. https://doi.org/10.1111/dom.14863
Chapelsky, S., Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P., Wallenstein, S. O. R., & Roux, C. W. L. (2022). Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults With Overweight/Obesity in the STEP 1 Trial. Canadian Journal of Diabetes, 46(7), S4–S5. https://doi.org/10.1016/j.jcjd.2022.09.012
Perreault, L., Davies, M., Frias, J. P., Laursen, P. N., Lingvay, I., Machineni, S., Varbo, A., Wilding, J. P., Wallenstein, S. O. R., & Roux, C. W. L. (2022). Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 45(10), 2396–2405. https://doi.org/10.2337/dc21-1785
Rosenstock, J., Garvey, W. T., Goldman, B., Khalid, U., Sørrig, R., & Rubino, D. (2022). 1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8). Diabetes, 71(Supplement_1). https://doi.org/10.2337/db22-1413-p
